Share this article
Share this article
NEW YORK, July 28, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ( Axsome or the Company ) (NASDAQ: AXSM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Axsome and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 14, 2021, Axsome disclosed in a filing with the U.S. Securities and Exchange Commission that it has been notified by the U.S. Food and Drug Administration (the FDA ) that the FDA is rescinding the Company s Breakthrough Therapy Designation for its AXS-12 product candidate for the treatment of cataplexy in narcolepsy, due to the FDA approving an additional drug product for the treatment of cataplexy in narcolepsy subsequent to granting AXS-12 Breakthrough Therapy Designation.
Redirecting to U S Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Form S-1/A Caribou Biosciences,
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.